drugset / Trial / NCT04290039

Sublingual vs IV Atropine Bioavailability Study

NCT04290039

RandomizedCrossoverOpen-labelTreatment

Summary

This randomized, three-sequence, three-period, phase 1 study is designed to assess the bioavailability and pharmacokinetics (PK) of sublingually administered atropine sulfate ophthalmic solution 1% USP (at 0.5 mg and 1.0 mg; test) compared to atropine sulfate injection administered IV (1.0 mg; reference).

Timeline

Start
2020-01-04
Primary completion
2020-02-02
Completion
2020-02-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atropine Other / unclassified 0.5 mg Subcutaneous
Comparator Atropine Other / unclassified 1 mg Subcutaneous

Indications